2024年7月8日 · Blinatumomab (Blincyto) is an injectable immunotherapy treatment that may be used to treat B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children aged 1 month and older. It is a biologic treatment that is usually given after other cancer treatments have been tried without success.

Blinatumomab, sold under the brand name Blincyto, is a biopharmaceutical medication used for the treatment of Philadelphia chromosome -negative relapsed or refractory acute lymphoblastic leukemia. [9] .

WHAT IS BLINCYTO ® (blinatumomab)? B-cell precursor acute lymphoblastic leukemia (ALL) in remission when only a small number of cancer cells remain in the body (minimal residual disease)...read more. This site is intended for US residents only. Talk to your doctor at diagnosis about adding BLINCYTO® to your treatment plan after initial therapy.

2024年10月23日 · Blincyto (blinatumomab) is commonly used to treat certain acute lymphoblastic leukemia (ALL) cancers. Blincyto may also be used for other conditions as determined by your healthcare provider. How...

2025年3月1日 · Blinatumomab injection is used to treat B-cell precursor acute lymphoblastic leukemia (ALL) in remission with minimal residual disease (MRD). It is also used to treat ALL that has come back or after other medicines did not work well.

2024年7月24日 · Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having a measurable residual disease (MRD)–negative complete remission with combination...

2017年3月2日 · In this multi-institutional phase 3 trial, we randomly assigned adults with heavily pretreated B-cell precursor ALL, in a 2:1 ratio, to receive either blinatumomab or standard-of-care...

Use the preservative-free preparations of BLINCYTO ® where possible in neonates.

Blinatumomab is a type of immunotherapy drug called a bispecific T-cell engager (BiTE). FDA label information for this drug is available at DailyMed. Blinatumomab is approved to treat: B-cell acute lymphoblastic leukemia that is CD19 positive in …

BLINCYTO is indicated for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children. A treatment course consists of 1 cycle of BLINCYTO...